06:50 AM EDT, 04/02/2025 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said Wednesday that it priced an underwritten offering of about 9.9 million common shares at $20.13 per share for total proceeds of about $200 million.

Proceeds from the offering, which is set to close Thursday, will be used to support the potential US commercial launch of sevasemten in patients with Becker muscular dystrophy and advance sevasemten's phase 3 trial in Duchenne muscular dystrophy.

Remaining proceeds will also be used for the ongoing research and development programs, as well as for general corporate purposes, the company added.